Seattle Genetics has dosed the first patient in the innovaTV 204 trial, a Phase ll study examining the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for treating patients with recurrent and/or metastatic cervical cancer.
The global, multicentre, single arm trial will include around 100 patients with recurrent and/or metastatic cervical cancer who progressed on or relapsed after treatment with platinum-based chemotherapy used alone or in combination with bevacizumab (Avastin).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of the trial, the patients will receive single-agent tisotumab vedotin every three weeks.
The trial’s primary goal is objective response rate as assessed by independent review.
Its key secondary endpoints comprise duration of response, progression-free survival, overall survival, safety and tolerability.
innovaTV 204 trial principal investigator Robert Coleman said: “While significant advances have been made in the treatment and prevention of cervical cancer, there remains a need for targeted agents that are effective for patients who progress or relapse after standard treatments.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“In a prior study, tisotumab vedotin demonstrated encouraging results in previously treated recurrent and/or metastatic cervical cancer, an area of unmet need where there is no established standard of care and response rates are limited.”
Tisotumab vedotin is an investigational antibody-drug conjugate (ADC) currently being developed by Seattle Genetics along with Genmab.
It is designed to target Tissue Factor antigen on cancer cell surfaces and deliver the cell-killing agent monomethyl auristatin E (MMAE) directly inside cancer cells.
Seattle Genetics, in collaboration with Genmab, also plans to examine tisotumab vedotin in other solid tumours with unmet medical need for new treatment options.
